SLN
Silence Therapeutics plc
$6.69
+0.15%
$313.1M
No data for this timeframe.
Vol
Market Cap$313.1M
Cap SizeSmall Cap
Inst. Holders23 funds
Inst. Value$12.8M
Inst. Activity3 buys / 2 sells
Insider Activity2B / 2S
SEC Reports1
Recent Activity
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: SLN124 (Phase 2)
Trial: Study to Assess SLN124 in Patients With Polycythemia Vera
Sponsor: Silence Therapeutics plc
P
Mar 5, 2026
SEC
Silence Therapeutics reported a significant year-over-year decline in revenue and increased net loss, driven by the conc
8-K — Impact 6/10
Oct 27, 2025
Insider
Griffiths Richard Ian sold 2,000 shares
10%+ Owner
Oct 27, 2025
Insider
Griffiths Richard Ian bought 2,000 shares
10%+ Owner
Aug 3, 2025
Insider
Griffiths Richard Ian bought 20,000 shares
10%+ Owner
Inst.
BlackRock, Inc. — DOUBLED
204,777 shares ($1.1M)
Inst.
BANK OF MONTREAL /CAN/ — ADD
202,901 shares ($1.1M)
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$31.20 (Mar 2026)
Current $6.69
Low $4.00
Median $25.00
High $75.00
5 analysts
$4.00
$75.00
Analyst Ratings
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 13, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.11 ▼ -10.0% | $-0.11 — $-0.11 | 80% YoY | 1 |
| Next Q | $-0.10 | $-0.10 — $-0.10 | 33% YoY | 1 |
| Current FY | $-0.40 ▼ -2.6% | $-0.40 — $-0.40 | 78% YoY | 1 |
| Next FY | $-0.39 | $-0.39 — $-0.39 | 3% YoY | 1 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | TRIM |
| CITADEL ADVISORS LLC | $6.5M | DOUBLED |
| BlackRock, Inc. | $1.1M | DOUBLED |
| BANK OF MONTREAL /CAN/ | $1.1M | ADD |
| MARSHALL WACE, LLP | $893.9K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 27, 2025 | Griffiths Richard | SELL | $0.00 |
| Oct 27, 2025 | Griffiths Richard | BUY | $0.00 |
| Aug 3, 2025 | Griffiths Richard | BUY | $0.00 |
| Aug 3, 2025 | Griffiths Richard | SELL | $0.00 |
23 institutional holders with $12.8M total value (2,445,012 shares) as of 2026-Q1. Top holders: ROYAL, CITADEL, BlackRock,. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 16 | $0.00 | 0.0% | TRIM -42.2% |
| 2 | CITADEL ADVISORS LLC | 1,234,807 | $6.5M | 50.8% | DOUBLED +274.0% |
| 3 | BlackRock, Inc. | 204,777 | $1.1M | 8.4% | DOUBLED +179.9% |
| 4 | BANK OF MONTREAL /CAN/ | 202,901 | $1.1M | 8.3% | ADD +26.4% |
| 5 | MARSHALL WACE, LLP | 169,616 | $893.9K | 7.0% | ADD +87.1% |
| 6 | HSBC HOLDINGS PLC | 122,834 | $640.0K | 5.0% | TRIM -28.9% |
| 7 | Point72 Asset Management, L.P. | 119,711 | $630.9K | 4.9% | NEAR_EXIT -97.5% |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 115,281 | $607.5K | 4.7% | — |
| 9 | MORGAN STANLEY | 65,486 | $345.1K | 2.7% | NEAR_EXIT -79.8% |
| 10 | GOLDMAN SACHS GROUP INC | 52,511 | $276.7K | 2.2% | — |
| 11 | BANK OF AMERICA CORP /DE/ | 29,773 | $156.9K | 1.2% | DOUBLED +903.8% |
| 12 | RAYMOND JAMES FINANCIAL INC | 25,000 | $131.8K | 1.0% | — |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 20,200 | $106.5K | 0.8% | — |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 18,900 | $99.6K | 0.8% | — |
| 15 | TWO SIGMA INVESTMENTS, LP | 16,203 | $85.4K | 0.7% | TRIM -37.8% |
| 16 | RHUMBLINE ADVISERS | 13,935 | $73.4K | 0.6% | DOUBLED +121.6% |
| 17 | CITADEL ADVISORS LLC | 11,300 | $59.6K | 0.5% | DOUBLED +274.0% |
| 18 | BARCLAYS PLC | 2,937 | $15.5K | 0.1% | ADD +83.8% |
| 19 | Mirae Asset Global Investments Co., Ltd. | 2,450 | $12.9K | 0.1% | ADD +25.7% |
| 20 | JONES FINANCIAL COMPANIES LLLP | 2,500 | $12.3K | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 73,153 | 204,777 | +179.9% | $1.1M | 2026-Q1 |
| BANK OF MONTREAL /CAN/ | ADD | 160,474 | 202,901 | +26.4% | $1.1M | 2026-Q1 |
| HSBC HOLDINGS PLC | TRIM | 172,834 | 122,834 | -28.9% | $640.0K | 2026-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 324,630 | 65,486 | -79.8% | $345.1K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 2,966 | 29,773 | +903.8% | $156.9K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 1,207,724 | 324,630 | -73.1% | $2.0M | 2025-Q4 |
| MARSHALL WACE, LLP | ADD | 83,219 | 155,680 | +87.1% | $946.5K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 63,247 | 39,344 | -37.8% | $239.2K | 2025-Q4 |
| RHUMBLINE ADVISERS | DOUBLED | 5,865 | 12,999 | +121.6% | $79.0K | 2025-Q4 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 1,816 | 2,282 | +25.7% | $13.9K | 2025-Q4 |
| UBS Group AG | ADD | 228,509 | 307,363 | +34.5% | $1.6M | 2025-Q3 |
| MARSHALL WACE, LLP | TRIM | 175,862 | 83,219 | -52.7% | $431.9K | 2025-Q3 |
| BlackRock, Inc. | TRIM | 168,235 | 61,832 | -63.2% | $320.9K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 5,095 | 3,531 | -30.7% | $18.3K | 2025-Q3 |
| UBS Group AG | TRIM | 319,514 | 228,509 | -28.5% | $1.3M | 2025-Q2 |
| Woodline Partners LP | TRIM | 134,492 | 62,459 | -53.6% | $362.3K | 2025-Q2 |
| RHUMBLINE ADVISERS | DOUBLED | 1,875 | 6,196 | +230.5% | $35.9K | 2025-Q2 |
| ROYAL BANK OF CANADA | TRIM | 4,263 | 2,462 | -42.2% | $14.0K | 2025-Q2 |
| MARSHALL WACE, LLP | TRIM | 488,889 | 228,418 | -53.3% | $644.1K | 2025-Q1 |
| BANK OF MONTREAL /CAN/ | DOUBLED | 65,007 | 158,593 | +144.0% | $447.2K | 2025-Q1 |
| Walleye Capital LLC | DOUBLED | 36,397 | 136,150 | +274.1% | $383.9K | 2025-Q1 |
| Woodline Partners LP | TRIM | 498,732 | 134,492 | -73.0% | $379.3K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 142,052 | 76,008 | -46.5% | $214.3K | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 499,066 | 64,886 | -87.0% | $183.0K | 2025-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 633,100 | 16,032 | -97.5% | $45.2K | 2025-Q1 |
1 unique insiders with 4 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 27, 2025 | Griffiths Richard Ian | 10%+ Owner | SELL | 2,000 | — | — |
| Oct 27, 2025 | Griffiths Richard Ian | 10%+ Owner | BUY | 2,000 | — | — |
| Aug 3, 2025 | Griffiths Richard Ian | 10%+ Owner | BUY | 20,000 | — | — |
| Aug 3, 2025 | Griffiths Richard Ian | 10%+ Owner | SELL | 20,000 | — | — |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 6.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$31.20 mean target (Mar 2026)
$4.00 Low
$75.00 High
| Metric | Value |
|---|---|
| Current Price | $6.69 |
| Target Low | $4.00 |
| Target Mean | $31.20 |
| Target Median | $25.00 |
| Target High | $75.00 |
| # Analysts | 5 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.11 | $-0.11 | $-0.11 | 80.0% | -10.0% | 0↑ 1↓ | $0.0B | 523.2% | 1 |
| Next Q 2026-09-30 |
$-0.10 | $-0.10 | $-0.10 | 33.3% | +0.0% | 1↑ 0↓ | $0.0B | 737.8% | 1 |
| Current FY 2026-12-31 |
$-0.40 | $-0.40 | $-0.40 | 78.4% | -2.6% | 0↑ 1↓ | $0.0B | 582.9% | 1 |
| Next FY 2027-12-31 |
$-0.39 | $-0.39 | $-0.39 | 2.5% | +0.0% | 1↑ 0↓ | $0.0B | 44.3% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.110 | |
| 7d ago | $-0.100 | -0.010 |
| 30d ago | $-0.100 | -0.010 |
| 60d ago | $-0.100 | -0.010 |
| 90d ago | $-0.460 | +0.350 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 13, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
Clinical Trial
Study to Assess SLN124 in Patients With Polycythemia Vera
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: SLN124 (Phase 2)
Trial: Study to Assess SLN124 in Patients With Polycythemia Vera
Sponsor: Silence Therapeutics plc
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Cond
Apr 24, 2026
short_interest
FTD: SLN — 78,743 shares ($0.6M) failed to deliver
Settlement: 20260424, Price: $7.84, FTD Value: $617,345.12, SILENCE THERAPEUTICS PLC SPONS